Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.47 |
| ▸ | DGAT1 | O75907 | 7/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.41 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10185129 | 0.92 | PARP15 (0.48) | HRH3DGAT1NR1H4NPC1PARP15 | |
| SCHEMBL10186419 | 0.90 | PARP15 (0.50) | HRH3DGAT1NR1H4PARP15PARP10 | |
| SCHEMBL10184929 | 0.90 | HRH3 (0.40) | HRH3DGAT1KDM4ELMNANR1H4 | |
| SCHEMBL10184403 | 0.85 | DGAT1 (0.54) | HRH3DGAT1KDM4ELMNA | |
| SCHEMBL10185016 | 0.83 | RAB9A (0.59) | HRH3DGAT1NPC1 | |
| SCHEMBL10185018 | 0.83 | RAB9A (0.59) | HRH3DGAT1NPC1 | |
| SCHEMBL10185118 | 0.82 | MAPT (0.48) | DGAT1KDM4ELMNANPC1 | |
| SCHEMBL10185424 | 0.82 | HRH3 (0.55) | HRH3DGAT1KDM4ELMNA | |
| SCHEMBL10185235 | 0.82 | NR1H4 (0.43) | DGAT1NR1H4NPC1PARP15PARP10 | |
| SCHEMBL10184323 | 0.82 | DGAT1 (0.56) | HRH3DGAT1LMNANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
| WO-2010122968-A1 | DIACYLETHYLENEDIAMINE COMPOUND | アステラス製薬株式会社 (JP) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | HRH3 2422/4885DGAT1 1/4885KDM4E 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.